Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to B/F/TAF in HIV-1 Infected Women
NCT02652624Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With HIV-1 RNA >= 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm. Started Feb 2016; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02652624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652624.